Peptide Attorney in Charlotte, North Carolina

Not the clinical practice itself. The North Carolina Medical Board’s position is that a business practicing medicine must be owned entirely by holders of active North Carolina licenses, or by one of the licensee combinations G.S. 55B-14 permits, such as a physician together with a physician assistant or nurse practitioner. A non-licensee can own a management services organization that contracts with that licensee-owned entity for the non-clinical side of the business on arm’s-length terms.

Prescribing is a medical judgment, but sourcing is a regulatory question. BPC-157 has no FDA-approved version, no USP monograph, and is not on the FDA’s 503A bulks list, so as of 2 November 2026 a pharmacy cannot lawfully compound it under section 503A, even after the FDA’s April 2026 Category 2 change and the July 2026 advisory committee vote in its favor. A draft HHS policy published on 30 October 2026 says HHS does not intend to take enforcement action against 503A compounding, under the policy’s conditions, with the six peptides in its Appendix A, BPC-157 among them; that is a statement about enforcement, not a change to the list. A clinic needs to know where each substance sits before building a protocol around it.

The process has started for some. In July 2026 an FDA advisory committee voted to recommend six peptides, BPC-157 among them, for the 503A bulks list. That recommendation does not bind the FDA, and a substance is added only through notice-and-comment rulemaking, which had not begun as of 2 November 2026. On 30 October 2026 HHS published a draft enforcement discretion policy for 503A compounding with six peptides listed in its Appendix A: BPC-157, epitalon, KPV, MOTS-c, Semax and TB-500 (91 FR 68526). It is a draft and a statement about enforcement, not a rule, and the list itself is set by regulation. Until the list changes, those peptides cannot lawfully be compounded under section 503A.

No. The Federal Register notice describes enforcement discretion for compounding under section 503A by a state-licensed pharmacy, a federal facility or a licensed physician. A 503B outsourcing facility cannot rely on it, and a clinic planning office stock should check the 503B rules separately.

Often not at the outset. It depends on whether outside investors, a non-clinical business partner or a future sale are part of the plan. Outside investors cannot buy into the clinical entity itself: G.S. 55B-6 limits its shares to licensed professionals, and a non-compliant issuance or transfer is void. Where outside capital or an operator is part of the plan, putting a management services organization in place early lets them come in at that level later, without restructuring the clinical entity.

Only by meeting the rules of each state where a patient is located. That usually means a prescriber licensed in, or registered with, that state, and compliance with its telemedicine and corporate-practice rules. Multi-state telehealth needs a state-by-state plan rather than a single national template, and where another state’s law governs, the firm works with counsel admitted there.

Structuring work, including entity formation and the management services agreement, is scoped and priced before it starts. Ongoing compliance and advertising review run on a defined retainer. Hourly billing is reserved for litigation and genuinely open-ended matters.